Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating Clinical and Economic Benefits of Lenzilumab | national company


BURLINGAME, Calif.–(BUSINESS WIRE)–January 18, 2022–

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called a “cytokine storm,” today announced a publication at peer-reviewed in the Journal of Medical Economics ( citing the associated clinical and economic benefits of lenzilumab. The publication demonstrated, in all cases, that lenzilumab plus SOC improved all specified clinical outcomes compared to SOC alone. Lenzilumab plus SOC resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after assumed price of $10,000 for lenzilumab) in patients receiving remdesivir with protein C- reactive (CRP) baseline

“This publication demonstrates the potential for significant cost savings to healthcare systems, while improving patient outcomes,” said Dr. Adrian Kilcoyne, Chief Medical Officer at Humanigen. “With the current rise of omicron, the importance of variant-independent therapies that are both clinically effective and cost-effective is paramount.”

This peer-reviewed publication highlights the significant costs of treating hospitalized patients with COVID-19 and the economic benefits of potentially improving ventilation-free survival, ventilator use, recovery time , mortality, ICU time, and invasive mechanical ventilation time, which may be associated with adding lenzilumab to the standard of care from a US hospital perspective.

“During these unprecedented and challenging times, we are preparing to commercialize lenzilumab as a one-day therapy that is variant-agnostic and, if licensed, a driver of clinical and economic value for patients and systems. healthcare,” said Edward P. Jordan, Chief Business Officer, Humanigen.

About Humanigen

Lenzilumab is an investigational product and is not approved or licensed in any country.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called a “cytokine storm”. Lenzilumab is a first-in-class antibody that binds and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate that GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in cytokine storm. Early in the COVID-19 pandemic, investigation showed that elevated levels of GM-CSF-secreting T cells were associated with disease severity and intensive care unit admission. Hunigen’s LIVE-AIR Phase 3 study suggests that early intervention with lenzilumab could prevent the consequences of a true cytokine storm in hospitalized patients with COVID-19. Humanigen is developing lenzilumab as a treatment for the cytokine storm associated with CAR-T cell therapies targeted at COVID-19 and CD19 and is also exploring the efficacy of lenzilumab in other inflammatory conditions such as acute graft versus graft disease. host in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. The PREACH-M chronic myelomonocytic leukemia study at 5 centers in Australia has started dosing patients. The SHIELD study in CAR-T and the RATinG study in acute graft versus host disease (aGvHD) are expected to begin recruiting in the first half of 2022 in the US and UK respectively. Other COVID studies to be completed or initiated in 2022 include the NIH-sponsored ACTIV-5/BET-B study in the United States and Korea and the ongoing C-SMART study in Australia. All are late-stage clinical studies. Furthermore, Humanigen is pursuing a Phase 1 program focused on ifabotuzumab in solid tumors.

For more information, visit and follow Humanigen on LinkedIn, Twitter and Facebook.

Forward-looking statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgments and expectations regarding future performance or events. Although management believes that the expectations reflected in these statements are reasonable, it does not guarantee that these expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will”, “expect”, “intend”, “plan”, “potential”, “possible”, “goals”, “accelerate”, “continue” and similar expressions identify forward-looking statements, including, without limitation, statements regarding the potential benefits of lenzilumab, if authorized or endorsed; statements regarding our clinical trial programs; and other statements regarding our plans for lenzilumab and ifabotuzumab.

Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks inherent in our lack of profitability and our need for additional capital to grow our business; our reliance on partners to further develop our product candidates; the uncertainties inherent in developing, obtaining required regulatory clearances and approvals, and launching any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the “Risk Factors” sections of our most recent annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary statement. You should not rely on forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unforeseen events, or to update the reasons why actual results could differ materially. of those anticipated in the forward-looking statements, in each case, except as required by law.

See the source version on

CONTACT: Humanigen Investor Relations

Timothy E. Morris COO & CFO Humanigen, Inc.




SOURCE: Humanigen, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 01/18/2022 05:55 / DISK: 01/18/2022 05:56


About Author

Comments are closed.